ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders

ReShape Lifesciences与主要机构股东完成4600万美元融资

2021-07-01 13:30:10 biospace


Funding provides for the acceleration of its internal growth strategy and the continued development of Reshape's weight-loss portfolio SAN CLEMENTE, CA / ACCESSWIRE / June 30, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global physician-led weight-loss and metabolic health solutions company, today provided additional information about its previously announced warrant exercise agreement with existing accredited investors for approximately $46 million in gross proceeds. The company is currently anchored by the Lap-Band® System with over 1,000,000 worldwide placements and the company's recently launched reshapecare™ virtual health program, both reimbursed through major insurance carriers. ReShape plans to use the proceeds from the transaction to expand patient direct marketing activities, advance their internal product pipeline and general corporate purposes. Additionally, the company will repay in full the outstanding principal and accrued interest under its secured credit agreement dated March 25, 2020. "We are highly encouraged by the momentum we have achieved thus far in 2021 through our recent listing on The Nasdaq Capital Market, merger with Obalon and this empowering capital investment. Our strategic execution has afforded us the opportunity to grow our financial visibility, eliminate debt overhang and optimize our ability to focus on key growth priorities. With this bolstered financial position and an expanded portfolio of innovative weight loss products and services, we look forward to the second half of 2021 being a truly transformative time for ReShape," said Bart Bandy, President and Chief Executive Officer of ReShape LifeSciences. "This significant infusion of funding in combination with our continued focus on a conservative spending approach places the company in an ideal position to consider and execute strategic initiatives geared towards growth," commented Thomas Stankovich, Chief Financial Officer of ReShape Lifesciences. "Now, with a strengthened balance sheet and a fully shielded IP portfolio, we are poised to drive commercial operations that can capture an even greater share of the growing weight-loss market while maintaining our focus on increasing shareholder value." Maxim Group LLC acted as the exclusive placement agent for the transaction. About ReShape Lifesciences Inc. ReShape Lifesciences is America's premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The recently launched reshapecare™ virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. Forward-Looking Safe Harbor Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the company's intended use of proceeds from the transaction and the company's strategic initiatives going forward. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks identified under the heading "Risk Factors" in ReShape's Annual Report on Form 10-K, which was filed with the SEC on March 11, 2021, and Obalon Therapeutics, Inc.'s Annual Report on Form 10-K, filed with the SEC on March 12, 2021, as well as both companies' subsequent Quarterly Reports on Form 10-Q and other information filed by each company with the SEC. These and additional risks and uncertainties are described more fully in ReShape's and Obalon's filings with the SEC. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. Company Contact: Thomas Stankovich Chief Financial Officer ReShape Lifesciences Inc. 949-276-6042 Investor Contacts: James Salierno/Daniel Kontoh-Boateng Vice President The Ruth Group 646-536-7028/7019 SOURCE: ReShape Lifesciences Inc. View source version on
资金用于加速其内部增长战略和Reshape减肥投资组合的持续发展 加州圣克莱门特/ACCESSWIRE/2021年6月30日/重塑生命科学公司(Nasdaq:RSLS)是一家全球医生领导的减肥和代谢健康解决方案公司,今天提供了关于其此前宣布的与现有认证投资者的认股权证行使协议的额外信息,该协议的总收益约为4600万美元。该公司目前由宽带®系统和该公司最近推出的ReshapeCare™虚拟健康计划所支撑,该系统在全球拥有超过100万个职位,两者都通过主要保险公司报销。 重塑计划将交易所得用于扩大患者直接营销活动,推进其内部产品管道和一般企业目的。此外,本公司将全数偿还其日期为2020年3月25日的担保信贷协议项下的未偿还本金及应计利息。 “通过最近在纳斯达克资本市场上市、与奥巴隆的合并以及这一赋权资本投资,我们在2021年迄今取得的势头令我们深受鼓舞。我们的战略执行为我们提供了提高财务能见度、消除债务负担和优化专注于关键增长优先事项的能力的机会。重塑生命科学总裁兼首席执行官巴特·班迪(Bart Bandy)表示:”随着财务状况的改善和创新减肥产品和服务组合的扩大,我们期待2021年下半年成为重塑的真正变革时期。“ ReShape Lifesciences首席财务官托马斯·斯坦科维奇(Thomas Stankovich)评论说:“这种大量的资金注入,加上我们继续专注于保守的支出方法,使公司处于一个理想的位置,可以考虑和执行面向增长的战略举措。”“现在,随着资产负债表的加强和完全保护的知识产权组合,我们准备推动商业运营,在不断增长的减肥市场中获得更大的份额,同时保持我们对增加股东价值的关注。” Maxim Group LLC为本次交易的独家配售代理。 关于重塑生命科学公司。 ReShape Lifesciences是美国首屈一指的减肥解决方案公司,提供管理和治疗肥胖和代谢疾病的成熟产品和服务的综合组合。美国食品和药物管理局批准的膝带®系统提供了微创、长期的肥胖症治疗,是更有创的外科缝合程序的替代方案,如胃旁路手术或袖状胃切除术。重塑背心™系统是一种研究性(在美国以外)微创、腹腔镜植入的医疗设备,包裹在胃周围,模仿传统减肥手术的胃体积缩小效果。它有助于快速减轻肥胖和病态肥胖患者的体重,而不会永久改变患者的解剖结构。最近推出的ReshapeCare™虚拟健康教练项目是一个虚拟远程健康体重管理项目,支持所有减肥患者改变生活方式,帮助他们随着时间的推移保持体重。 前瞻性安全港声明: 本新闻稿包含1995年私人证券诉讼改革法案含义范围内的前瞻性陈述。这些前瞻性陈述通常可以通过使用诸如“预期”、“计划”、“预期”、“可能”、“可能”、“打算”、“将会”、“继续”、“未来”等词以及其他类似含义的词和使用未来日期来识别。本新闻稿中的前瞻性陈述包括关于公司交易所得款项的预期用途和公司未来战略举措的陈述。这些前瞻性陈述基于我们管理层目前的预期,涉及已知和未知的风险和不确定性,这些风险和不确定性可能导致我们的实际结果、业绩或成就与前瞻性陈述所表达或暗示的任何未来结果、业绩或成就存在重大差异。此类风险和不确定性包括,除其他外,Reshape于2021年3月11日向美国证券交易委员会提交的10-K表格年度报告和Obalon Therapeutics,Inc.于2021年3月12日向美国证券交易委员会提交的10-K表格年度报告中在“风险因素”标题下确定的风险,以及两家公司随后向美国证券交易委员会提交的10-Q表格季度报告和其他信息。这些以及额外的风险和不确定性在Reshape和Obalon提交给SEC的文件中得到了更充分的描述。我们在本新闻稿发布之日提供这些信息,并且不承担任何义务,因为新的信息、未来事件或其他原因而更新本文件中包含的任何前瞻性陈述,除非法律要求。 公司联系方式: 托马斯·斯坦科维奇 财务总监 重塑生命科学公司。 949-276-6042 投资者联系人: 詹姆斯·萨利尔诺/丹尼尔·孔托-博阿滕 副总裁 露丝集团 646-536-7028/7019 资料来源:重塑生命科学公司。 在AccessWire.com上查看源版本: